Company

Fulcrum Therapeutics, Inc.

Public · FULC

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapies to treat genetically defined rare diseases.

Fulcrum Therapeutics, Inc. is a publicly traded company. It trades under the ticker FULC. Leadership tracked by CEOInsider includes Gregory Oakes (CEO).

www.fulcrumtx.com ↗LinkedIn ↗

Leadership

Current

Gregory Oakes

CEO

Recent developments

AI summary of recent coverage

Recent coverage has focused on Fulcrum Therapeutics' all-stock merger with Slate Medicines, backed by a $245 million financing round and a planned dividend to Fulcrum shareholders. The deal has also attracted investor investigations into potential securities law violations and questions regarding fair valuation for public shareholders.

Summarized from the headlines in the sidebar; see each source for the full story.